Malika Sapargaliyeva
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Malika Sapargaliyeva has a total of 23 co-authors. Here are the top co-authors by number of shared publications:
- Aidos Bolatov
Shenzhen University Medical School, Shenzhen University, Shenzhen, China
4 shared publications - Aizhan Abdikadirova
Clinical Academic Department of Laboratory Medicine, Pathology, and Genetics “University Medical Center” Corporate Fund Astana Kazakhstan
4 shared publications - Mirgul Bayanova
Clinical Academic Department of Laboratory Medicine, Pathology, and Genetics “University Medical Center” Corporate Fund Astana Kazakhstan
4 shared publications - Dias Malik
“University Medical Center” Corporate Fund, Astana, Kazakhstan
3 shared publications - Lyazzat Nazarova
“University Medical Center” Corporate Fund, Astana, Kazakhstan
3 shared publications - Yuriy Pya
“University Medical Center” Corporate Fund, Astana, Kazakhstan
3 shared publications
Latest Publications
- Open Access
- 8 September 2026
- Published by Wiley in Brain Pathology
Molecular profiling of pediatric medulloblastoma in Kazakhstan: Genomic alterations, subgroup distribution, and survival
Medulloblastoma is the most common malignant pediatric brain tumor and comprises biologically distinct molecular subgroups with different clinicopathologic and prognostic characteristics. Molecular data from Kazakhstan and other underrepresented regions remain limited, and practical approaches for molecular subgroup assignment using formalin‐fixed, paraffin‐embedded (FFPE) material are needed in settings where advanced molecular classification is not routinely available. We retrospectively analyzed 40 pediatric medulloblastomas diagnosed between 2015 and 2024 at the Corporate Fund “University Medical Center,” Kazakhstan. Archived FFPE tumor material underwent histologic review, immunohistochemical evaluation (β‐catenin, YAP1, and GAB1), and whole‐exome sequencing. Tumors were assigned to WNT, SHH, or non‐WNT/non‐SHH categories using a combined morphologic, immunophenotypic, and genomic framework, and clinicopathologic variables and overall survival were evaluated across subgroups. WNT medulloblastomas ( n = 7, 17.5%) showed the most canonical profile, characterized by classic histology, uniform β‐catenin nuclear positivity, recurrent CTNNB1 / APC alterations, and frequent chromosome 6 loss. SHH medulloblastomas ( n = 10, 25.0%) were enriched for desmoplastic/nodular morphology, frequent YAP1/GAB1 expression, pathogenic PTCH1 / SUFU alterations, and additional events involving TP53 , TERT , and focal amplifications in a subset. Non‐WNT/non‐SHH medulloblastomas ( n = 23, 57.5%) showed the greatest genomic heterogeneity, including frequent i17q and broader structural complexity. Clinically, WNT tumors occurred predominantly in older children and had the most favorable survival, whereas non‐WNT/non‐SHH tumors were the only subgroup associated with metastatic disease at presentation and showed the poorest long‐term survival. Overall, pediatric medulloblastoma in this cohort demonstrated subgroup‐specific patterns consistent with established biology. The integration of pathology, immunohistochemistry, and sequencing enabled clinically meaningful molecular stratification. These findings expand evidence from an underrepresented setting and support pragmatic, resource‐adapted profiling in routine practice.
- 8 September 2026
- Published by Wiley in Brain Pathology
Open AccessMolecular profiling of pediatric medulloblastoma in Kazakhstan: Genomic alterations, subgroup distribution, and survival
Medulloblastoma is the most common malignant pediatric brain tumor and comprises biologically distinct molecular subgroups with different clinicopathologic and prognostic characteristics. Molecular data from Kazakhstan and other underrepresented regions remain limited, and practical approaches for molecular subgroup assignment using formalin‐fixed, paraffin‐embedded (FFPE) material are needed in settings where advanced molecular classification is not routinely available. We retrospectively analyzed 40 pediatric medulloblastomas diagnosed between 2015 and 2024 at the Corporate Fund “University Medical Center,” Kazakhstan. Archived FFPE tumor material underwent histologic review, immunohistochemical evaluation (β‐catenin, YAP1, and GAB1), and whole‐exome sequencing. Tumors were assigned to WNT, SHH, or non‐WNT/non‐SHH categories using a combined morphologic, immunophenotypic, and genomic framework, and clinicopathologic variables and overall survival were evaluated across subgroups. WNT medulloblastomas ( n = 7, 17.5%) showed the most canonical profile, characterized by classic histology, uniform β‐catenin nuclear positivity, recurrent CTNNB1 / APC alterations, and frequent chromosome 6 loss. SHH medulloblastomas ( n = 10, 25.0%) were enriched for desmoplastic/nodular morphology, frequent YAP1/GAB1 expression, pathogenic PTCH1 / SUFU alterations, and additional events involving TP53 , TERT , and focal amplifications in a subset. Non‐WNT/non‐SHH medulloblastomas ( n = 23, 57.5%) showed the greatest genomic heterogeneity, including frequent i17q and broader structural complexity. Clinically, WNT tumors occurred predominantly in older children and had the most favorable survival, whereas non‐WNT/non‐SHH tumors were the only subgroup associated with metastatic disease at presentation and showed the poorest long‐term survival. Overall, pediatric medulloblastoma in this cohort demonstrated subgroup‐specific patterns consistent with established biology. The integration of pathology, immunohistochemistry, and sequencing enabled clinically meaningful molecular stratification. These findings expand evidence from an underrepresented setting and support pragmatic, resource‐adapted profiling in routine practice.
- Open Access
- 5 November 2025
- Published by Springer Nature in BMC Nephrology
- Vol. 26 (1) , 1-18
Whole-exome sequencing of kidney transplant recipients and donors: insights into end-stage renal disease and post-transplant genetic risk
Kidney transplantation is the preferred treatment for end-stage renal disease (ESRD), yet challenges persist in long-term graft survival and post-transplant complications. Genomic profiling, especially whole-exome sequencing (WES), offers new opportunities to personalize donor-recipient matching and predict transplant outcomes. This study aimed to explore the genetic landscape of both transplant recipients and donors using WES. This prospective cohort study included 64 kidney transplant recipients (51 adults, 13 pediatric) and 61 donors in Kazakhstan. WES was performed to identify monogenic causes of ESRD, evaluate rejection-associated immune polymorphisms (31 SNPs), and screen for post-transplant risk using a 355-gene Transplant Morbidity Panel. Variants were classified following ACMG/AMP guidelines, and allele frequencies were compared to global reference datasets. Among recipients, pathogenic/likely pathogenic variants were found in 15.4% of pediatric and 9.1% of adult cases, with additional variants of uncertain significance detected in 23.1% and 23.6%, respectively. WES identified monogenic nephropathies including Alport syndrome, cystinuria, and polycystic kidney disease. In donors, 13.1% carried variants associated with latent renal or systemic conditions despite no clinical manifestation at donation. The APOE p.Cys130Arg variant, linked to lipid dysregulation, was observed more frequently in recipients (allele frequency 0.17) than donors (0.09), though not statistically significant. Among the 31 SNPs evaluated, significant associations with acute rejection were observed for IL1B rs1143634 and TP53 rs1625895 under dominant models. IL1B carriers showed increased rejection risk (OR = 4.62, p = 0.039), whereas TP53 carriers appeared protected (OR = 0.058, p = 0.027). Given the limited number of rejection cases, these findings should be considered exploratory and require validation in larger cohorts. Additionally, 44.3% of recipients carried at least one pathogenic or likely pathogenic variant in the Transplant Morbidity Panel, particularly in genes related to malignancy, cardiomyopathy, and monogenic diabetes. This study provides one of the first applications of WES in a Central Asian kidney transplant population. Findings highlight the prevalence of monogenic and comorbid risk variants in both recipients and donors and support the use of genomic screening for improving pre- and post-transplant care. The identification of immune-related SNPs and extra-renal findings further underscores the utility of WES for personalized transplant management. Integration of genomics into transplant workflows may help address the ongoing gap between clinical need and transplant outcomes, particularly in low-resource settings.
- 5 November 2025
- Published by Springer Nature in BMC Nephrology
- Vol. 26 (1) , 1-18
Open AccessWhole-exome sequencing of kidney transplant recipients and donors: insights into end-stage renal disease and post-transplant genetic risk
Kidney transplantation is the preferred treatment for end-stage renal disease (ESRD), yet challenges persist in long-term graft survival and post-transplant complications. Genomic profiling, especially whole-exome sequencing (WES), offers new opportunities to personalize donor-recipient matching and predict transplant outcomes. This study aimed to explore the genetic landscape of both transplant recipients and donors using WES. This prospective cohort study included 64 kidney transplant recipients (51 adults, 13 pediatric) and 61 donors in Kazakhstan. WES was performed to identify monogenic causes of ESRD, evaluate rejection-associated immune polymorphisms (31 SNPs), and screen for post-transplant risk using a 355-gene Transplant Morbidity Panel. Variants were classified following ACMG/AMP guidelines, and allele frequencies were compared to global reference datasets. Among recipients, pathogenic/likely pathogenic variants were found in 15.4% of pediatric and 9.1% of adult cases, with additional variants of uncertain significance detected in 23.1% and 23.6%, respectively. WES identified monogenic nephropathies including Alport syndrome, cystinuria, and polycystic kidney disease. In donors, 13.1% carried variants associated with latent renal or systemic conditions despite no clinical manifestation at donation. The APOE p.Cys130Arg variant, linked to lipid dysregulation, was observed more frequently in recipients (allele frequency 0.17) than donors (0.09), though not statistically significant. Among the 31 SNPs evaluated, significant associations with acute rejection were observed for IL1B rs1143634 and TP53 rs1625895 under dominant models. IL1B carriers showed increased rejection risk (OR = 4.62, p = 0.039), whereas TP53 carriers appeared protected (OR = 0.058, p = 0.027). Given the limited number of rejection cases, these findings should be considered exploratory and require validation in larger cohorts. Additionally, 44.3% of recipients carried at least one pathogenic or likely pathogenic variant in the Transplant Morbidity Panel, particularly in genes related to malignancy, cardiomyopathy, and monogenic diabetes. This study provides one of the first applications of WES in a Central Asian kidney transplant population. Findings highlight the prevalence of monogenic and comorbid risk variants in both recipients and donors and support the use of genomic screening for improving pre- and post-transplant care. The identification of immune-related SNPs and extra-renal findings further underscores the utility of WES for personalized transplant management. Integration of genomics into transplant workflows may help address the ongoing gap between clinical need and transplant outcomes, particularly in low-resource settings.
- Open Access
- 14 November 2024
- Published by Semey Medical University in Наука и здравоохранение
- No. 4(26),p. 177-189
GENETIC BIOMARKERS OF ACUTE GRAFT REJECTION AFTER HEART TRANSPLANTATION
Heart transplantation (HT) is the standard of care for end-stage heart failure refractory to medical therapy. Patients after heart transplantation are at risk of developing various complications during their follow-up. Common complications include early allograft failure, acute graft rejection (AGR), coronary allograft vasculopathy (CAV), renal failure, infections, and cancer. Causes for secondary graft dysfunction need to be considered beyond the first week. Nowadays, histological stratification of acute rejection (AR) on endomyocardial biopsy plus histopathology (EMBx) is the standard method for diagnosing acute rejection, assessing its severity, and the response to therapy. Unfortunately, this method is invasive and has some limitations. In addition to that, acute rejection has two phenotypes, acute cellular rejection (ACR) and antibody-mediated rejection (AMR), which challenges the histopathologic diagnosis. Secondary non-genetic methods for monitoring cardiac rejection may include echocardiography, cardiac MRI, troponin, and other methods. A reliable non-invasive marker to detect acute rejection prior to the development of graft dysfunction would possibly result in better outcomes for those patients who develop allograft rejection. In the current review, we collect recent data about genetic non-invasive biomarkers including donor derived cell free DNA, DNA-methylation, RNAs Gene expression profiling (messenger RNA) and micro-RNA. cfDNA methylation analysis can help to distinguish different types of acute rejection. The fraction of cfDNA from the donor decreases rapidly post-transplantation, and increase only in case of acute rejection or myocardial injury. In summary, genetic non-invasive methods have a pivotal role in the assessing and monitoring cardiac allograft rejection. Review article established that DNA-based non-invasive tools minimize the risks of invasive procedures. It is a safe, convenient, and precise method for diagnosing heart failure after cardiac transplantation. Трансплантация сердца является стандартом лечения терминальной сердечной недостаточности, резистентной к медикаментозной терапии. Пациенты после трансплантации сердца подвергаются риску развития различных осложнений во время наблюдения. Распространенные осложнения включают раннюю недостаточность аллотрансплантата, острое отторжение трансплантата, коронарную васкулопатию аллотрансплантата, почечную недостаточность, инфекции и рак. Причины вторичной дисфункции трансплантата необходимо учитывать после первой недели трансплантации. На сегодняшний день, гистологическая стратификация острого отторжения при помощи эндомиокардиальной биопсии с гистопатологией является стандартным методом диагностики острого отторжения, оценки его тяжести и ответа на терапию. К сожалению, этот метод инвазивный и имеет некоторые ограничения. В дополнение к этому острое отторжение имеет два фенотипа: острое клеточное отторжение и антитело-опосредованное отторжение, что затрудняет постановку гистопатологического диагноза. Вторичные негенетические методы мониторинга сердечного отторжения могут включать эхокардиографию, МРТ сердца, тропонин и другие методы. Надежный неинвазивный маркер для выявления острого отторжения до развития дисфункции трансплантата, возможно, приведет к лучшим результатам для тех пациентов, у которых есть вероятность развития отторжения аллотрансплантата. В нашем обзоре мы собрали последние данные о генетических неинвазивных биомаркерах, включая внеклеточную ДНК донорского происхождения, метилирование ДНК, профилирование экспрессии генов РНК (матричная РНК) и микро-РНК. Анализ метилирования внеклеточной ДНК может помочь различить различные типы острого отторжения. Метод микро-РНК может сыграть важную роль в будущем как цель разработки иммунодепрессантов. В основе анализа внеклеточной ДНК донорского происхождения лежит обнаружение однонуклеотидных полиморфизмов, отличающих ДНК донора от ДНК реципиента. Фракция внеклеточной ДНК донора быстро снижается после трансплантации и увеличивается только в случае острого отторжения или повреждения миокарда. Таким образом, генетические неинвазивные методы...
- 14 November 2024
- Published by Semey Medical University in Наука и здравоохранение
- No. 4(26),p. 177-189
Open AccessGENETIC BIOMARKERS OF ACUTE GRAFT REJECTION AFTER HEART TRANSPLANTATION
Heart transplantation (HT) is the standard of care for end-stage heart failure refractory to medical therapy. Patients after heart transplantation are at risk of developing various complications during their follow-up. Common complications include early allograft failure, acute graft rejection (AGR), coronary allograft vasculopathy (CAV), renal failure, infections, and cancer. Causes for secondary graft dysfunction need to be considered beyond the first week. Nowadays, histological stratification of acute rejection (AR) on endomyocardial biopsy plus histopathology (EMBx) is the standard method for diagnosing acute rejection, assessing its severity, and the response to therapy. Unfortunately, this method is invasive and has some limitations. In addition to that, acute rejection has two phenotypes, acute cellular rejection (ACR) and antibody-mediated rejection (AMR), which challenges the histopathologic diagnosis. Secondary non-genetic methods for monitoring cardiac rejection may include echocardiography, cardiac MRI, troponin, and other methods. A reliable non-invasive marker to detect acute rejection prior to the development of graft dysfunction would possibly result in better outcomes for those patients who develop allograft rejection. In the current review, we collect recent data about genetic non-invasive biomarkers including donor derived cell free DNA, DNA-methylation, RNAs Gene expression profiling (messenger RNA) and micro-RNA. cfDNA methylation analysis can help to distinguish different types of acute rejection. The fraction of cfDNA from the donor decreases rapidly post-transplantation, and increase only in case of acute rejection or myocardial injury. In summary, genetic non-invasive methods have a pivotal role in the assessing and monitoring cardiac allograft rejection. Review article established that DNA-based non-invasive tools minimize the risks of invasive procedures. It is a safe, convenient, and precise method for diagnosing heart failure after cardiac transplantation. Трансплантация сердца является стандартом лечения терминальной сердечной недостаточности, резистентной к медикаментозной терапии. Пациенты после трансплантации сердца подвергаются риску развития различных осложнений во время наблюдения. Распространенные осложнения включают раннюю недостаточность аллотрансплантата, острое отторжение трансплантата, коронарную васкулопатию аллотрансплантата, почечную недостаточность, инфекции и рак. Причины вторичной дисфункции трансплантата необходимо учитывать после первой недели трансплантации. На сегодняшний день, гистологическая стратификация острого отторжения при помощи эндомиокардиальной биопсии с гистопатологией является стандартным методом диагностики острого отторжения, оценки его тяжести и ответа на терапию. К сожалению, этот метод инвазивный и имеет некоторые ограничения. В дополнение к этому острое отторжение имеет два фенотипа: острое клеточное отторжение и антитело-опосредованное отторжение, что затрудняет постановку гистопатологического диагноза. Вторичные негенетические методы мониторинга сердечного отторжения могут включать эхокардиографию, МРТ сердца, тропонин и другие методы. Надежный неинвазивный маркер для выявления острого отторжения до развития дисфункции трансплантата, возможно, приведет к лучшим результатам для тех пациентов, у которых есть вероятность развития отторжения аллотрансплантата. В нашем обзоре мы собрали последние данные о генетических неинвазивных биомаркерах, включая внеклеточную ДНК донорского происхождения, метилирование ДНК, профилирование экспрессии генов РНК (матричная РНК) и микро-РНК. Анализ метилирования внеклеточной ДНК может помочь различить различные типы острого отторжения. Метод микро-РНК может сыграть важную роль в будущем как цель разработки иммунодепрессантов. В основе анализа внеклеточной ДНК донорского происхождения лежит обнаружение однонуклеотидных полиморфизмов, отличающих ДНК донора от ДНК реципиента. Фракция внеклеточной ДНК донора быстро снижается после трансплантации и увеличивается только в случае острого отторжения или повреждения миокарда. Таким образом, генетические неинвазивные методы...
- Open Access
- 25 April 2024
- Published by JSC National Scientific Medical Research Center in Journal of Clinical Medicine of Kazakhstan
- Vol. 21 (2) , 11-17
Influence of Genetic Polymorphisms in CYP3A5, CYP3A4, and MDR1 on Tacrolimus Metabolism after kidney transplantation
Kidney transplantation stands as the ultimate recourse for restoring vital organ functions, particularly in cases of end-stage kidney disease where alternative treatments, such as dialysis, prove less effective. With over 102,000 kidney transplants conducted globally in 2022, the demand for organ transplantation is ever-increasing, fueled by a rising incidence of end-stage renal disease attributed to causes like diabetes and hypertension. Despite significant advancements in kidney transplantation, immunosuppressive therapy remains crucial to preventing graft rejection. Tacrolimus (TAC), a calcineurin inhibitor, plays a pivotal role in this regard. Discovered in 1984, TAC inhibits T-lymphocyte activation, preventing acute rejection by disrupting the transcription of crucial genes involved in early T-cell activation. However, the use of TAC is not without challenges. The drug exhibits serious side effects, a narrow therapeutic index, and unpredictable pharmacokinetics. Therapeutic drug monitoring (TDM) becomes imperative in daily practice to maintain TAC blood concentrations within the therapeutic range. This literature review delves into the genetic aspects influencing TAC metabolism, focusing on key polymorphisms in CYP3A5, CYP3A4, and ABCB1 genes. Genetic variations in CYP3A5, a major enzyme in TAC metabolism, impact enzyme activity, necessitating personalized dosing strategies. CYP3A4 polymorphisms, especially CYP3A4*22, demonstrate associations with altered TAC clearance and dose requirements. The ABCB1 gene, encoding P-glycoprotein, another player in TAC pharmacokinetics, also exhibits polymorphisms influencing drug absorption and distribution. The ABCB1 3435C>T variant, in particular, shows potential implications on Tacrolimus bioavailability. Understanding these genetic variations aids in the development of personalized dosing regimens. Studies suggest that tailoring TAC doses based on CYP3A5 genotypes significantly improves the proportion of patients achieving therapeutic concentrations. Additionally, incorporating genetic information, particularly CYP3A4*22, into dosing strategies enhances the precision of TAC therapy, reducing the risk of adverse effects.
- 25 April 2024
- Published by JSC National Scientific Medical Research Center in Journal of Clinical Medicine of Kazakhstan
- Vol. 21 (2) , 11-17
Open AccessInfluence of Genetic Polymorphisms in CYP3A5, CYP3A4, and MDR1 on Tacrolimus Metabolism after kidney transplantation
Kidney transplantation stands as the ultimate recourse for restoring vital organ functions, particularly in cases of end-stage kidney disease where alternative treatments, such as dialysis, prove less effective. With over 102,000 kidney transplants conducted globally in 2022, the demand for organ transplantation is ever-increasing, fueled by a rising incidence of end-stage renal disease attributed to causes like diabetes and hypertension. Despite significant advancements in kidney transplantation, immunosuppressive therapy remains crucial to preventing graft rejection. Tacrolimus (TAC), a calcineurin inhibitor, plays a pivotal role in this regard. Discovered in 1984, TAC inhibits T-lymphocyte activation, preventing acute rejection by disrupting the transcription of crucial genes involved in early T-cell activation. However, the use of TAC is not without challenges. The drug exhibits serious side effects, a narrow therapeutic index, and unpredictable pharmacokinetics. Therapeutic drug monitoring (TDM) becomes imperative in daily practice to maintain TAC blood concentrations within the therapeutic range. This literature review delves into the genetic aspects influencing TAC metabolism, focusing on key polymorphisms in CYP3A5, CYP3A4, and ABCB1 genes. Genetic variations in CYP3A5, a major enzyme in TAC metabolism, impact enzyme activity, necessitating personalized dosing strategies. CYP3A4 polymorphisms, especially CYP3A4*22, demonstrate associations with altered TAC clearance and dose requirements. The ABCB1 gene, encoding P-glycoprotein, another player in TAC pharmacokinetics, also exhibits polymorphisms influencing drug absorption and distribution. The ABCB1 3435C>T variant, in particular, shows potential implications on Tacrolimus bioavailability. Understanding these genetic variations aids in the development of personalized dosing regimens. Studies suggest that tailoring TAC doses based on CYP3A5 genotypes significantly improves the proportion of patients achieving therapeutic concentrations. Additionally, incorporating genetic information, particularly CYP3A4*22, into dosing strategies enhances the precision of TAC therapy, reducing the risk of adverse effects.